19 completed, 11 unknown, 6 terminated, 5 recruiting. 21 Phase 2, 16 Phase 3, 6 Not applicable, 6 Phase 1.
Follow Transarterial chemoembolization: new trials by email Literature Review of Transarterial chemoembolization trials Research Report on Transarterial chemoembolization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment Transarterial chemoembolization, durvalumab and tremelimumab - HCC, Tace | Phase 2 | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2026-09-15 | 2026-08-06 |
| Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer Transarterial chemoembolization - Unresectable Colorectal Cancer, Advanced Malignancy | Phase 2 | Not yet recruiting | Junpeng Wang | 50 | 2025-10-01 | 2025-10-07 |
| Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere NRT6003 Injection, cTACE - Unresectable Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Chengdu New Radiomedicine Technology Co. LTD. | 108 | 2025-04-15 | 2026-06-09 |
| Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors Sulfur Hexafluoride Lipid Microspheres, Contrast-Enhanced Ultrasound, Transarterial Chemoembolization - Liver Neoplasms | Phase 2 | Recruiting | john eisenbrey | 266 | 2024-08-07 | 2026-02-17 |
| A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization Atezolizumab, Bevacizumab, Transarterial Chemoembolization - Unresectable Hepatocellular Carcinoma | Completed | Hoffmann-La Roche | 113 | 2024-07-19 | 2025-03-21 | |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma GKL-006 Injection, transarterial chemoembolization - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1 | Completed | Beijing Gene Key Life Technology Co., Ltd | 13 | 2024-04-16 | 2026-09-28 |
| Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization - Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Phase 2 | Terminated | Yale University | 3 | 2023-06-07 | 2025-01-15 |
| Phase II Trial of Lung Chemoemobolization Computed Tomography, Ethiodized Oil, Mitomycin - Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm | Phase 2 | Recruiting | City of Hope Medical Center | 30 | 2023-05-12 | 2026-03-05 |
| Transarterial Chemoembolization With Lipiodol in the Treatment of Initial Unresectable Gastric Cancer (GC) Transarterial Chemoembolization - Gastric Cancer, Embolization | Phase 2 | Unknown | Gang Wu | 60 | 2022-06-01 | 2022-05-24 |
| HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure Hepatic Artery Infusion Chemotherapy, Transarterial Chemoembolization, Regorafenib - Hepatocellular Carcinoma | Not applicable | Unknown | The Central Hospital of Lishui City | 176 | 2022-02-01 | 2022-02-10 |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma TACE, Lenvatinib, Anti-PD-1 monoclonal antibody - Hepatocellular Carcinoma Non-resectable | Unknown | Tongji Hospital | 300 | 2022-01-20 | 2024-06-13 | |
| A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection Tislelizumab, TACE - Hepatocellular Carcinoma, Adjuvant Therapy | Phase 2 | Unknown | Zhejiang University | 50 | 2021-11-08 | 2022-01-05 |
| Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Carmustine, Ethiodized Oil, Transarterial Chemoembolization - Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma | Phase 2 | Active not recruiting | Thomas Jefferson University | 28 | 2021-09-27 | 2026-05-06 |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma Atezolizumab, Bevacizumab, TACE - Hepatocellular Carcinoma | Phase 3 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 434 | 2021-07-06 | 2025-01-07 |
| Evaluate the Effect of Tirazamine on Primary Liver Cancer. tirapazamine, Transarterial Embolization, TACE - Hepato Cellular Carcinoma (HCC) | Phase 1 / Phase 2 | Terminated | Zhejiang Raygene Pharmaceuticals Co., Ltd | 16 | 2021-05-14 | 2025-02-27 |
| Perioperative Therapy for Hepatocellular Carcinoma Sintilimab Injection, TACE, Radiotherapy - Hepatocellular Carcinoma | Phase 2 | Terminated | Zhejiang University | 10 | 2020-12-26 | 2022-01-11 |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma Nivolumab, Ipilimumab, Cabozantinib - Hepatocellular Carcinoma, HCC | Phase 2 | Recruiting | University of California, Irvine | 35 | 2020-08-07 | 2026-10-26 |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC Sorafenib, Transarterial chemoembolization - Hepatocellular Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 158 | 2019-09-15 | 2020-03-25 |
| Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma transarterial chemoembolization, TACE plus RT - Hepatocellular Carcinoma | Not applicable | Withdrawn | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-07-31 | 2020-02-24 | |
| Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma Stereotactic Body Radiation, Transarterial Chemoembolization - Hepatocellular Carcinoma | Phase 3 | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 128 | 2019-05-27 | 2025-03-11 |
Showing 20 of 50. Sign in to see all of them.
Carcinoma, Hepatocellular (38) · Liver Neoplasms (7) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Hepatitis C (1) · Hyperbilirubinemia (1) · Mediastinal Neoplasms (1) · Neuroendocrine Tumors (1) · Pleural Neoplasms (1) · Recurrence (1) · Sarcoma (1) · Stomach Neoplasms (1) · Uveal Melanoma (1)
Sun Yat-sen University (6) · Zhejiang University (3) · Abramson Cancer Center at Penn Medicine (2) · Guangxi Medical University (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Stanford University (2) · Accuray Incorporated (1) · Asan Medical Center (1) · Beijing Gene Key Life Technology Co., Ltd (1) · Brno University Hospital (1) · Case Comprehensive Cancer Center (1) · Chang Gung Memorial Hospital (1) · Chengdu New Radiomedicine Technology Co. LTD. (1) · City of Hope Medical Center (1) · Dalin Tzu Chi General Hospital (1)
China (18) · United States (14) · Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Taiwan (2) · Argentina (1) · Austria (1) · Egypt (1) · South Korea (1) · Spain (1)
Ming Shi, MD (4) · Daniel Chang, MD (2) · Albert Koong, MD, PhD (1) · Caifang Ni, M.D (1) · Carin Gonsalves, MD (1) · Daniel T Chang (1) · Elshazly Sheta, Professor (1) · Erqi Liu Pollom, MD (1) · Farshid Dayyani, MD, PhD (1) · Ferial El-kalla, Professor (1) · Franz E Boas, MD (1) · Gaojun Teng (1) · Han Chu Lee, M.D (1) · Ibrahim Amer, Consultant (1)
PMID 30016989, PMID 30922261, PMID 32576496, PMID 32712254, PMID 33615957, PMID 34648352, PMID 37611799, PMID 38568599, PMID 40302359
2005 (1), P30CA033572 (1), P30CA043703 (1), P30CA124435 (1), R01CA194307 (1)